Frontage Laboratories, a full-service CRO based in Andover, Mass., has acquired BDM Consulting, of Summerset, N.J. The acquisition expands Frontage's current capabilities and strengthens its full-service drug and medical device development services across both North America and Asia.
Frontage has acquired a 45% interest in BDM and now exclusively co-owns BDM along with Hangzhou Tigermed Consulting. BDM is an independent CRO specializing in biostatistics, data management and SAS programming.
"This acquisition strengthens our offering and will further enhance Frontage's position as a complete and personalized development services partner with specialized expertise," said Song Li, Ph.D., CEO at Frontage. "Frontage continues to grow our portfolio of capabilities to help clients reduce the time and cost of product development."
BDM will continue to operate independently under the leadership of Sam Liang, M.D., its founder and president. The acquisition is expected to enhance BDM's market position across the North American and Asian markets as well.
"This is a strategic combination of Frontage's clinical development expertise with our biometrics services," said Liang. "Both organizations will benefit by being able to offer clients a more comprehensive solution for clinical trial support."